Neumora Therapeutics, Inc. (NMRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $69.43M
Last updated: Nov 17, 2026 at 4:17 PM ET
Neumora Therapeutics, Inc. (NMRA) Statistics
Neumora Therapeutics (NMRA) has a market cap of $69.43M and an enterprise value of $37.08M. Its share count is up 16.10% from a year earlier. It holds $32.35M more cash than debt, 46.60% of its market cap.
Total Valuation
Enterprise value is 46.60% below the market cap, as cash exceeds debt.
| Market Cap | $69.43M |
|---|---|
| Enterprise Value | $37.08M |
| Latest price (Nov 17, 2026) | $0.33 |
Key Dates
| Last Earnings Date | Nov 16, 2026 |
|---|---|
| Fiscal Year End | December |
Price Statistics
The stock is down 87.38% over 52 weeks and trades 41.07% below its 50-day average.
| Beta (1Y) | 0.74 |
|---|---|
| 52-Week Change | -87.38% |
| 1-Month Change | -28.83% |
| 3-Month Change | -79.60% |
| 6-Month Change | -79.97% |
| Total Return (1Y) | -87.38% |
| Total Return (3Y CAGR) | -69.70% |
| Max Drawdown (1Y) | -90.68% |
| Max Drawdown (3Y) | -98.31% |
| Sharpe Ratio (1Y) | -1.61 |
| Correlation with SPY (1Y) | 0.08 |
| 50-Day Average | $0.56 |
| 200-Day Average | $1.69 |
| 52-Week Range | $0.32 to $3.65 |
| RSI (14 Days) | 33.2 |
| Average Volume (20 Days) | 1.61M |
Financial Position
Current assets cover 4.08x current liabilities, and total debt is 2.87x shareholder equity.
| Current Ratio | 4.08x |
|---|---|
| Quick Ratio | 4.08x |
| Debt / Equity | 2.87x |
| Interest Coverage | -24.82x |
Returns and Efficiency
Return on invested capital is -260.49% and return on equity is -1026.52% over the last 12 months.
| Return on Equity (ROE) | -1026.52% |
|---|---|
| Return on Assets (ROA) | -200.36% |
| Return on Invested Capital (ROIC) | -260.49% |
| Return on Capital Employed (ROCE) | -260.49% |
| ROA (5Y Average) | -66.89% |
Scores
NMRA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Operating Income | -$186.94M |
| Pretax Income | -$190.40M |
| Net Income | -$190.43M |
| EBITDA | -$186.46M |
| EBIT | -$187.17M |
| Reported EPS (TTM) | -$1.06 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 19.52% of the $95.05M in total assets.
| Cash and Equivalents | $85.65M |
|---|---|
| Total Debt | $53.30M |
| Net Cash | $32.35M |
| Net Cash Per Share | $0.17 |
| Working Capital | $71.55M |
| Shareholder Equity | $18.55M |
| Book Value Per Share | $0.10 |
| Total Assets | $95.05M |
| Total Liabilities | $76.50M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$167.33M |
|---|---|
| FCF Per Share | -$0.89 |
| Depreciation and Amortization | $1.74M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -53.60% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -53.60% |
Dividends and Yields
NMRA does not pay a dividend.
| Buyback Yield | -67.29% |
|---|---|
| Shareholder Yield | -67.29% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About NMRA
What is NMRA's market cap?
Neumora Therapeutics has a market cap of $69.43M. Its enterprise value, which adds debt and subtracts cash, is $37.08M.
How many shares of NMRA are outstanding?
Neumora Therapeutics has 187.90M shares outstanding. The count is up 16.10% from a year earlier.
Does NMRA pay a dividend?
No. Neumora Therapeutics does not pay a dividend.
How much debt does NMRA have?
Neumora Therapeutics has $53.30M of total debt and $85.65M of cash and equivalents, a net cash position of $32.35M.
NMRA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors